6-Keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent
- 1 August 1980
- journal article
- research article
- Published by Elsevier in Prostaglandins
- Vol. 20 (2), 391-400
- https://doi.org/10.1016/s0090-6980(80)80056-6
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- 6-keto-prostaglandin E1 inhibits the aggregation of human plateletsEuropean Journal of Pharmacology, 1979
- Hypotensive and renovascular actions of 6-keto-prostaglandin E1, a metabolite of prostacyclinEuropean Journal of Pharmacology, 1979
- Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregationProstaglandins, 1979
- Reversal of platelet aggregation by prostacyclinPharmacological Research Communications, 1978
- Effects of prostacyclin (PGX) on cyclic AMP concentrations in human plateletsProstaglandins, 1977
- Modulation of human platelet adenylate cyclase by prostacyclin (PGX)Prostaglandins, 1977
- Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxidesProstaglandins, 1976
- An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature, 1976
- Platelet aggregation in partially obstructed vessels and its elimination with aspirin.Circulation, 1976
- Radioimmunoassay for Cyclic NucleotidesJournal of Biological Chemistry, 1972